Winston Wong, PharmD, Editor-in-Chief

The goal of this supplement is to provide a clearer perspective of the impact of AML upon the health care system, as well as the benefit of an AML clinical pathway.
Making the transition from fee-for-service reimbursement to value-based models of care and payments will be slow and difficult.
The promise of CAR-T therapies as a potential cure for cancers and the pressure that this creates in the market will likely serve to highlight the ineffective areas in our health care system, as providers contend with multiple barriers associated with the therapy.
It is an exciting time in oncology care as innovative cellular and gene therapies come to market, with many more to come in the near future.
Together, the articles in this issue emphasize the continued importance of not getting so carried away with technology, pre-approved plans, or theoretically ideal outcomes that the human aspect of medical care and care providers is lost.
Collectively, this issue of JCP presents how market dynamics are changing in relation to oncology practices, what providers are doing to evolve with these changes, and how clinical pathways are advancing these changes to achieve better care for patients.
As another year draws to a close, I look back on the work produced by Journal of Clinical Pathways with pride. But it is still important to keep our focus on what’s next.
New developments within the parameters of clinical pathways and value-based care offer many possibilities, and the current issue of Journal of Clinical Pathways offers a wide scope of where the field stands.
Medicine changes rapidly, but you can always count on Journal of Clinical Pathways for the latest information on value-based care.
For those of us at Journal of Clinical Pathways, September marks our Clinical Pathways Congress, held the weekend of September 8 in Washington, DC. Although the Congress may be our primary focus, it is certainly not the only iron we have in the fire.